A novel foot-and-mouth disease (FMD) diagnostic reagent has been developed by scientists at The Pirbright Institute. This has the potential to be used in FMD diagnostic tests, and will be significantly quicker to produce when compared to existing test reagents due to a simplified production technique.
In collaborative research led by The Pirbright Institute, scientists have generated a ‘hybrid’ foot-and-mouth disease virus (FMDV) with improved stability, which will increase its effectiveness when administered as a vaccine. They targeted the Southern African Territories (SAT) 2 serotype viruses, which are among the least stable of the seven different types of FMDV.
Under the leadership of Pirbright’s Dr Elma Tchilian the Comparative and Veterinary Immunology Group (CVIG) has been revived and is actively engaging in opportunities to showcase the research of its members and bring knowledge of comparative and veterinary immunology to a wider audience.
® The Pirbright Institute 2024 | A company limited by guarantee, registered in England no. 559784. The Institute is also a registered charity.
